Vista Partners

Click on the links below to access our latest news releases.

Vista News & Commentary

Vista Partners Updates Coverage on Mast Therapeutics, Inc.; Price Target $2.25

Posted on by

San Francisco, CA (July 18, 2013) — Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) (“MSTX“), a publicly traded biopharmaceutical company headquartered in San Diego, CA; with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, “MSTX completed an underwritten public offering in June with institutional investors that include Franklin Resources (NYSE: BEN), Deerfield Capital Management & others that collectively own approximately 50% of MSTX post the offering. Attracting these prestigious investors to fully fund their Phase 3 sickle cell trial is encouraging.” Mr. Silver continued, “Per the first quarter earnings release on May 15, 2013; MSTX has opened more than a dozen clinical sites in EPIC and is on track to meet its goal of opening approximately 40 U.S. sites by year-end.  MSTX plans to support U.S. enrollment by opening roughly 30 sites outside the U.S., beginning early next year.  MSTX remains the only company with a new drug in phase 3 development in sickle cell disease and investigators have been enthusiastic about the potential for MST-188 to become the first agent approved to treat an on-going vaso-occlusive crisis of sickle cell disease. Mr. Silver concluded, “MSTX also plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease.  Peripheral arterial disease affects an estimated 8 to 12 million people in the United States.”

To download a FREE copy of the Mast Therapeutics Inc. research report, please visit http://www.vistapglobal.com and click the “download research” icon to gain access to the report.

Please view a full list of Disclaimers which are available at http://www.vistapglobal.com/disclaimer/

3 comments
Nathan Folz
Nathan Folz

I hope their research finds a treatment for sickle cell, it would really help lots of people.

Jeff
Jeff

Seems like an exciting company, is the Phase 3 sickle cell trial data due in 2015?

National News

Categories

Archives

Feeds